DexCom, Inc. (DXCM)
| Market Cap | 27.15B |
| Revenue (ttm) | 4.03B |
| Net Income (ttm) | 576.20M |
| Shares Out | 392.11M |
| EPS (ttm) | 1.42 |
| PE Ratio | 48.62 |
| Forward PE | 34.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,613,129 |
| Open | 67.70 |
| Previous Close | 67.39 |
| Day's Range | 67.70 - 69.27 |
| 52-Week Range | 57.52 - 139.24 |
| Beta | 1.50 |
| Analysts | Strong Buy |
| Price Target | 99.00 (+43.0%) |
| Earnings Date | May 1, 2025 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time... [Read more]
Financial Performance
In 2024, DexCom's revenue was $4.03 billion, an increase of 11.34% compared to the previous year's $3.62 billion. Earnings were $576.20 million, an increase of 6.41%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price forecast is $99.0, which is an increase of 43.00% from the latest price.
News
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
The U.S. Food and Drug Administration approved DexCom, Inc.'s DXCM Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes.
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance
DexCom says its G7 15 Day system will land on the market in the second half of 2025.
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for peopl...
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will ho...
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
BURNABY, British Columbia--(BUSINESS WIRE)--The Government of Saskatchewan expands public coverage for Dexcom Continuous Glucose Monitoring Systems.
These 20 worst-performing stocks in the S&P 500 sank 17% or more in March
Stocks turned higher on Monday afternoon to finish March on a positive note. Still, the S&P 500 ended with a 5.8% decline for March, with 69% of component stocks down for the month.
Dexcom Appoints Jon Coleman as Chief Commercial Officer
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Jon Coleman as Chief Commercial Officer.
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform...
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of ...
History Says Shut Up And Buy: 12 Hyper-Growth Blue Chips To Buy Right Now
Market corrections, like the recent dip, are normal and temporary, with historical data showing average declines of 13-14% since 1950. Long-term investors should stay the course. Corrections often lea...
Dexcom Appoints Renée Galá to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Renée Galá to Board of Directors.
Dexcom receives FDA warning letter for two U.S. manufacturing facilities
Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its shares down near...
DexCom Gets FDA Warning Letter After Inspections of Facilities
DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response.
DexCom, Inc. (DXCM) Presents at 46th Annual Raymond James Institutional Investors Brokers Conference (Transcript)
DexCom, Inc. (NASDAQ:DXCM) 46th Annual Raymond James Institutional Investors Conference March 4, 2025 10:25 AM ET Company Participants Jereme Sylvain - Chief Financial Officer Matt Carey - Manager of...
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional Investors Conference on Tues...
Quality Key in Volatile Market, NFLX & DXCM Value Plays
Friday's trading session showed weakness is possible in the current market, and Lisa Schreiber says investors need to turn to quality in a time of volatility. Lisa expects the U.S. economy to bolster ...
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.
DexCom Analysts Increase Their Forecasts After Q4 Earnings
DexCom, Inc. DXCM reported weaker-than-expected earnings for its fourth quarter on Thursday.
DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairma...
Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast
Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results.
Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2...
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued,...
Dexcom forecasts 2025 revenue mostly in-line with expectations
Dexcom forecast total annual revenue in line with Wall Street expectations on Monday, on bets of strong demand for its continuous glucose monitors for diabetes patients.